A. Bouter

发表

Complement activating and opsonic capacity of monoclonal antibodies raised againstEscherichia coli O111 and its rough mutant J5

J. Verhoef, E. Brouwer, J. Marcelis, 1986, European Journal of Clinical Microbiology.

The Opsonic Capacity of Monoclonal Antibodies Against Escherichia Coli 0111 and Its Rough Mutant E. Coli J5

J. Verhoef, R. Vreede, A. Bouter, 1988 .

Antibiotics enhance binding of lipid A-specific murine monoclonal antibody E5 to Gram-negative bacteria.

J. Verhoef, J. Cornelissen, H. Snippe, 1994, International journal of antimicrobial agents.

Monoclonal antibodies specific for the phase-variant O-acetylated K1 capsule of Escherichia coli

M. Rozenberg-Arska, J. Verhoef, R. Torensma, 1991, Journal of clinical microbiology.

Cross-reactivity of monoclonal antibodies against lipopolysaccharides of gram-negative bacteria

J. Verhoef, J. Marcelis, J. Jongh-Leuvenink, 1986, European Journal of Clinical Microbiology.

New pyridine dithiols: Synthesis and structures of complexes with acids

R. Hulst, R. Kellogg, A. Meetsma, 1997 .

Binding characteristics and cross-reactivity of three different antilipid A monoclonal antibodies.

J. Verhoef, E. Brouwer, T. Erich, 1989, Journal of immunology.

Inability of lipid A murine specific monoclonal antibody E5 to neutralize lipopolysaccharide biological activity in vitro

J. Verhoef, J. Cornelissen, H. Snippe, 1994 .

Characterization and specification of monoclonal antibodies against Escherichia coli O111 and E. coli J5

J. Verhoef, J. Marcelis, J. Leuvenink, 1985, Antonie van Leeuwenhoek.